| Sector |
Medical Diagnostics
|
|---|---|
| Region |
Norwich
|
| Stage |
Commercialisation
|
| Fund | Life Sciences EIS |
| Target Raise |
£1m
|
Diagnostics and monitoring of respiratory disease using biomarkers in saliva.
The Investment Opportunity
COPD specifically refers to a group of lung conditions that cause breathing difficulty and mainly affects smokers in later life. According to the World Health Organisation, it is the third greatest cause of death worldwide. However, Glyconics advise it is currently an under-diagnosed condition with a high proportion of sufferers unaware of their diagnosis. To date, there is no existing state-of-the-art technology available to identify disease severity, disease progression or indicate early exacerbation (periods of time when symptoms can particularly flare up) in COPD.
The Company aims to address this unmet need through its innovative point-of-care test technology. Glyconics has developed a low-cost, easy-to-use, hand-held, miniaturised device for easy detection and monitoring by healthcare workers. The device works by simply applying a small saliva sample from a patient onto the surface of the device. The sample is internalised, and the composition is analysed by the Company’s unique software which identifies the infra-red spectrum pattern, with results given in less than 10 minutes. The result will give an indication of whether the patient has COPD and whether an exacerbation is imminent.
Milestones to Date
| 2017 | Deepbridge initially invested £150k via Deepbridge Life Sciences SEIS. |
|---|---|
| 2018 | Working with NHS Portsmouth for the collection of saliva samples for testing. |
| 2019 | Included in the Journal of MHealth, “Global Digital Health Top 100 Companies”. Featured in Business Weekly’s “Top 50 Ones to Watch”. |
| 2020 | Named as one of the “80 standout European start-up pioneers driving seismic change in the post-pandemic world” by FT-backed innovation website, Sifted.eu. Dr Niall Gallen, CTO named in the “#21toWatch people shortlist”. £140k grant awarded as part of the Defence and Security Accelerator (‘DASA’). Achieved ISO 13485 certification. |
Risks and Important Information
This page is a financial promotion for the purposes of Section 21 of the Financial Services and Markets Act 2000. The content of the page has been approved by Deepbridge Capital LLP. The Company may not gain the commercial traction that is forecast, it could experience development problems and may not be able to achieve its objectives. Please note that these risks are by no means exhaustive and there may be other risks which could have a material adverse impact on the Company’s financial performance. The content should not be construed as financial advice. Any decision to invest should be made only on the basis of the relevant documentation for each investment. Past performance is not necessarily a guide to future performance. The value of an investment may go down as well as up and investors could lose the total value of their investment. Investments in small unquoted companies carry a high- level of risk. These investments are highly illiquid and as such, there may not be a readily available market to sell such an investment. Tax treatment depends on the individual circumstances of each investor and may be subject to change in future. The availability of tax reliefs depends on the Company invested in maintaining its qualifying status. Deepbridge does not provide specific individual advice on the suitability of investments with regard to a potential investor’s individual circumstances, risk tolerance or investment objectives and investors should seek independent financial advice if they are in any doubt whether a product is suitable for them.